An enterprise value arbitrage opportunity, in a sidecar.

When I first wrote about MapLight Therapeutics (NASDAQ: MPLT), the attraction was the difference between the potential value of the ML-007C-MA program and the enterprise value of the company. There was a disconnect, and I took advantage of it in the run-up to the Phase 2 trial results.

The key factor was that Cobenfy had already done the difficult work of proving that M1/M4 muscarinic agonism—the same basic mechanism targeted by ML-007—could work in schizophrenia. Bristol Myers Squibb subsequently put a $14 billion price tag on that breakthrough when it acquired Karuna. Buying MPLT at a small enterprise value relative to that potential was an easy choice. So was taking profit on the way to the Phase 2 results.

You see, MapLight was deliberately trying to engineer a better implementation of one that had already been validated: better pharmacokinetics, easier dosing, less peripheral baggage and, hopefully, equal or better efficacy.

And the price seemed right. That was the original thesis and trade.

The Phase 2 ZEPHYR trial of ML-007C-MA succeeded. The 210/3 mg twice-daily dose met its primary endpoint in schizophrenia and produced supportive secondary results, along with an intriguing cognitive signal. But the headline efficacy result—a 4.5-point placebo-adjusted improvement in PANSS—wasn’t impressive enough to establish ML-007 as a superior Cobenfy. The market reacted and dumped the stock by approximately 70%.

But there is an important distinction between a disappointing result and a failed result. ZEPHYR disappointed relative to expectations. But it succeeded.

Raymond James made an interesting adjustment following the results. It increased its estimated probability of success in schizophrenia from 60% to 70%, while reducing estimated peak sales from roughly $1.6 billion to $1.1 billion.

So the clinical risk went down. The perceived commercial ceiling came down with it.

And the market treated it like it was broken.

Eyes on the Prize

What MapLight has done since is interesting.

The company has substantially narrowed its focus. It is concentrating resources on ML-007C-MA while pausing further investment in earlier preclinical and discovery-stage programs. ML-004, which produced an interesting irritability signal in autism despite missing its primary endpoint, may instead be advanced through strategic collaborations or alternative funding.

The company seems to have identified where the overwhelming majority of its value resides and is organizing itself accordingly to focus on ML-007C-MA.

Now, let’s follow the money.

MapLight ended June with $351 million in cash and investments. That was already a lot of firepower to advance the program. But shortly after the ZEPHYR results, the company raised another $150 million at $11.38 per share/share-equivalent despite already having a very healthy balance sheet.

Huh? What? That struck me as slightly odd. And worth looking into.

The financing participants included Deep Track, Baker Brothers, Forbion, Nan Fung and ADAR1, along with Goldman Sachs affiliates and Avego. A very nice lineup of biotech funders.

But more than half of the money—roughly $83 million—came from existing shareholder Catalyst4.

Catalyst4 is a billion-dollar, mission-driven investment and philanthropic organization funded by Google co-founder Sergey Brin. Unlike a conventional venture fund, it combines philanthropy with direct investment in mission-aligned companies, allowing it to provide substantial, patient, long-duration capital. CNS and neuroscience are among its principal areas of interest.

And it turns out Catalyst4’s relationship with MapLight extends well beyond its shareholding. Catalyst4 has longstanding ties to Brin’s neuroscience interests and family office and, prior to MapLight’s IPO, held contractual rights to designate three directors. Two of those designees—George Pavlov and Maria Walker—remain on MapLight’s board today. Pavlov is CEO of Bayshore Global Management, Brin’s family office.

So that makes what happened after ZEPHYR particularly interesting.

Catalyst4 didn’t retreat after seeing the less-than-spectacular efficacy result. It bought another roughly 1.2 million MapLight shares in the open market immediately following the readout, including one million shares at $13, and then committed approximately $83 million to the subsequent PIPE.

Following the financing, Catalyst4 holds approximately 25.3 million MapLight shares, plus pre-funded warrants for another 2.93 million shares. Against MapLight’s September 1 share count, that represents roughly 39% of currently outstanding common and non-voting common shares, or approximately 41% on a share-equivalent basis when the outstanding pre-funded warrants are included.

That’s an extraordinary commitment from the company’s dominant long-term backer.

Now that’s not proof that ML-007C-MA will succeed. Sophisticated and highly informed investors can be wrong.

But this isn’t an outside investor discovering MapLight after the stock collapsed either. This is the company’s dominant, deeply connected, long-term backer seeing the same ZEPHYR data the market saw—and materially increasing its commitment.

The financing also effectively removes capital availability as a near-term constraint. MapLight says its resources should fund ML-007C-MA through 2028, including VISTA in Alzheimer’s disease psychosis and ZEPHYR-2 in schizophrenia.

MapLight has essentially prepaid the journey through the major clinical milestones that should tell us what ML-007 actually is—and what it is worth.

There Is No Free Lunch

At a today’s (October 20, 2026) share price of $8.24, MapLight’s approximately 64.8 million outstanding common and non-voting common shares give it a basic market capitalization of roughly $533 million.

There are also approximately 4.0 million outstanding pre-funded warrants with a nominal $0.0001 exercise price. Economically, those are essentially shares. Including them takes the share-equivalent count to approximately 68.8 million and the corresponding market capitalization to roughly $567 million.

Against that, MapLight reported $351 million of cash and investments at June 30 and subsequently raised $150 million gross, giving it roughly $501 million on a pro-forma basis before financing expenses and subsequent cash burn.

The exact current cash balance won’t be known until the next financial report. Allowing reasonably for financing costs and ongoing Q3 spending, something in the area of $425–450 million appears a reasonable current estimate.

That would put the company’s current enterprise value at roughly $142–167 million.

This is intriguing for a company with a Phase 2-positive CNS asset heading toward a confirmatory schizophrenia trial and also in an approximately 300-patient Phase 2 Alzheimer’s disease psychosis trial.

But of course, the cash will be spent. MapLight burned roughly $60 million in Q2 alone, with $53.4 million of R&D expense.

If the company simply consumes $200–250 million annually building an independent pharmaceutical company, today’s relatively small enterprise value becomes considerably less interesting.

So my new question is:

How much cash must MapLight spend before reaching an event capable of radically changing the value of ML-007?

The Other Half of ML-007

Schizophrenia gets most of the attention, but Alzheimer’s disease psychosis may now be the more interesting part of the story.

VISTA is underway in approximately 300 patients, with results expected in the second half of 2027. ML-007C-MA already has FDA Fast Track designation in ADP, and Raymond James currently models roughly $2 billion of peak ADP sales versus $1 billion in schizophrenia.

There is also a fascinating external variable. Bristol Myers Squibb is developing Cobenfy in ADP. If its Phase 3 ADEPT program succeeds, BMS will have spent its own money helping answer one of the most important questions facing MapLight: whether muscarinic agonism works in Alzheimer’s psychosis.

That wouldn’t guarantee VISTA succeeds. But it could materially change the context in which VISTA is viewed.

Raymond James made another interesting observation following ZEPHYR. Before the results, its valuation included a 25% weighting for an M&A scenario. Afterwards, it removed that weighting while suggesting VISTA could be a gating step for greater strategic interest.

I wouldn’t interpret that as a FOR SALE sign. But I wouldn’t ignore it either.

A MapLight arriving in late 2027 with successful schizophrenia Phase 2 data, an agreed registrational pathway, ZEPHYR-2 underway, positive ADP data and substantial remaining cash would be a very different strategic asset with a very different value.

Perhaps MapLight commercializes ML-007 itself. Perhaps it partners it. Perhaps somebody decides they would rather own it.

The important thing is that MapLight has enough capital that it shouldn’t have to make that decision from a position of weakness.

A Different Setup

So my MapLight thesis has evolved. Originally, much of the asymmetry came from the possibility that ML-007 might emerge as an obviously superior version of Cobenfy. The P2 results made that argument harder.

But now we know that ML-007 appears to be a legitimate drug candidate with a positive probability of advancing.

It demonstrated statistically significant antipsychotic activity. Its convenience, simplified titration and lack of food restrictions may offer meaningful differentiation, while its overall tolerability profile remains encouraging. ADP represents a substantial second opportunity. And the company has enough capital to pursue the important questions without repeatedly returning to shareholders.

When I look at this from a ‘sidecar’ investment angle, management and its dominant long-term backer appear to be behaving as though they know exactly where the value resides. It might be a nice ride.

MapLight has narrowed spending around ML-007, while Catalyst4—closely tied to the company and to Sergey Brin’s broader neuroscience ecosystem—bought a lot more stock after ZEPHYR and then supplied more than half of the subsequent $150 million financing.

The situation as I see it equals:

Small EV + large cash balance + one increasingly focused lead asset + sophisticated backers + enough capital to reach multiple major value-inflection points without needing financing.

The cash burn matters. ZEPHYR-2 replication risk matters. VISTA can fail. A cheap biotech can remain cheap while efficiently converting cash into clinical trial expenses.

But MapLight increasingly looks like a very well-funded vehicle focused on determining the value of one potentially important CNS franchise.

They appear to know where the prize is. And the people financing the hunt appear to agree.

AI Disclosure: The author uses AI as a research and analytical tool. The thesis, research direction, source selection, assumptions and valuation framework are the work of the author. AI was used to accelerate the research process, test ideas, compare data, challenge assumptions and improve the writing clarity of the final work. The author uses AI as an enhancement and accelerant to the research process—Hopefully helping to produce higher-quality, more accurate and ultimately more useful research and analysis.